Medindia

X

Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors

Wednesday, July 7, 2010 Diabetes News J E 4
Advertisement

OXFORD, England, July 7, 2010 /PRNewswire-FirstCall/ -- Elsevier is pleased to announce the appointment of prominent new Editors-in-Chief to three key endocrinology titles, effective immediately.

Editor-in-Chief, Metabolism: Christos S. Mantzoros, MD DSc FACP FACE

Christos Mantzoros is clinical research lead at the Department of Endocrinology, Diabetes and Metabolism at Beth Israel Deaconess Medical Center, Boston, and associate professor of medicine at Harvard Medical School. He replaces James B. Field, who retires as Editor of Metabolism. Professor Mantzoros' research involves the discovery and elucidation of novel molecules central in the pathogenesis of diabetes, obesity, and related diseases. The Mantzoros group employs a wide range of basic, translational, and clinical approaches in this aim.

Editor-in-Chief, Primary Care Diabetes: Jaakko Tuomilehto, MD, PhD

Jaakko Tuomilehto succeeds Rhys Williams as Editor-in-Chief of Primary Care Diabetes. Professor Tuomilehto, University of Helsinki, has a broad and extensive experience in clinical epidemiology and genetic epidemiology of type 1 and type 2 diabetes. He is also an experienced coordinator of national studies in Finland and international collaborative studies, with a publishing record in excess of 900 papers comprising several landmark studies. Primary Care Diabetes is the official journal of Primary Care Diabetes Europe.

Editor-in-Chief, PLEFA: Richard P. Bazinet, PhD

Richard P Bazinet takes over the editorship of PLEFA (Prostaglandins, Leukotrienes and Essential Fatty Acids), from Mehar Manku, who remains as Editor Emeritus. Dr Bazinet, a former Associate Editor, is a researcher at the Faculty of Medicine, University of Toronto, and works to identify the mechanisms that regulate brain lipid metabolism and the role of brain lipid metabolism in the pathogenesis of neurodegenerative diseases and neuropsychiatric disorders. PLEFA is the official journal of the International Society for the Study of Fatty Acids and Lipids.

About Metabolism

This eminent journal ( http://www.elsevier.com/wps/find/journaldescription.cws_home/623319/descripti on#description) is regarded by clinicians and researchers alike as an authoritative source of practical information on metabolic processes and diseases in the areas of nutrition, genetics, dystrophies, diabetes and gout. Reviews and surveys on the status of research and practice in specific metabolic disorders are featured.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

About Primary Care Diabetes

The journal ( http://www.elsevier.com/wps/find/journaldescription.cws_home/710796/descripti on#description) publishes original research articles and high quality reviews in the fields of clinical care, diabetes education, nutrition, health services, psychosocial research and epidemiology and other areas as far as is relevant for diabetology in a primary-care setting. The purpose of the journal is to encourage interdisciplinary research and discussion between all those who are involved in primary diabetes care on an international level. The Journal also publishes news and articles concerning the policies and activities of Primary Care Diabetes Europe and reflects the society's aim of improving the care for people with diabetes mellitus within the primary-care setting.

About Prostaglandins, Leukotrienes & Essential Fatty Acids (PLEFA) (http://www.elsevier.com/wps/find/journaldescription.cws_home/623065/descript ion#description) The role of lipids, including essential fatty acids and their prostaglandin, leukotriene and other derivatives, is now evident in almost all areas of biomedical science. Cell membrane behaviour and cell signalling in all tissues are highly dependent on the lipid constituents of cells. Prostaglandins, Leukotrienes and Essential Fatty Acids aims to cover all aspects of the roles of lipids in cellular, organ and whole organism function, and places a particular emphasis on human studies. Papers concerning all medical specialties are published. Much of the material is particularly relevant to the development of novel treatments for disease.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Andrew Miller
    Executive Publisher, Elsevier
    Tel.: +44(0)1865-843823
    andrew.miller@elsevier.com

SOURCE Elsevier

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Nile Therapeutics Completes Dosing of Phase II Stu...
S
National Hearing Conservation Association (NHCA) A...